CRISPR Therapeutics

Phase A — Understand the business

Lens 1 · Company Overview

CRISPR Therapeutics AG is a Swiss-incorporated (Zug), Boston-operated (105 West First St, ~263,500 sq ft) gene-editing biopharma — the company that, with Vertex, took CRISPR/Cas9 from discovery to the first-ever approved CRISPR medicine, Casgevy (exa-cel), in 2023. It co-founded its science on Emmanuelle Charpentier's Nobel-winning work and exclusively in-licenses her worldwide Cas9 patent estate.

The business model is two companies stapled together:

1. A Casgevy royalty-stub. Under the Amended & Restated Vertex Joint Development & Commercialization Agreement (A&R Vertex JDCA), Vertex controls all research, development, manufacturing and commercialization of Casgevy worldwide; CRISP holds only observer/participation rights. Economics: net profits/losses on Casgevy are split 40% CRISPR / 60% Vertex (since July 2021). Critically, CRISP recognizes no product revenue from Casgevy — its 40% share flows through a single net line, "Collaboration expense, net," under ASC 808. So a "successful launch" shows up as a smaller expense, not as revenue.

2. A self-directed pipeline across four franchises:

• Hemoglobinopathies — Casgevy (approved); plus next-gen targeted-conditioning and in vivo HSC editing (with Vertex).
• In vivo liver editing — the strategic crown jewel CRISP owns outright: CTX310 (ANGPTL3, cardiovascular, Phase 1b), CTX340 (angiotensinogen, refractory hypertension), CTX321 (next-gen LPA), CTX460 (SERPINA1/AATD, on the proprietary SyNTase editing platform).
• CAR-T — zugocabtagene geleucel (zugo-cel, formerly CTX112; CD19) for autoimmune disease + oncology, made in-house at Framingham, MA.
• Regenerative medicine — CTX213, a deviceless beta-cell replacement for Type-1 diabetes.

Customers / suppliers / partners. End "customer" for Casgevy is the authorized-treatment-center channel that Vertex (not CRISP) owns. Key counterparties: Vertex (lead partner, ~the entire commercial P&L exposure), Sirius Therapeutics (May 2025 siRNA deal — CTX611/FXI), Eli Lilly (zugo-cel + pirtobrutinib combo in B-cell lymphoma), and Bayer (legacy). Payment structure: milestone + royalty + cost/profit-share — recurring but entirely contingent on partner-run programs.

One-line model: a development-stage editing platform that already minted one approved drug it doesn't control, sitting on ~$2.44B of cash, spending ~$0.5B/yr to turn its owned in-vivo pipeline into the next Casgevy.

Lens 2 · Supply Chain

Two distinct chains, because the modalities differ.

Casgevy (ex vivo, autologous) — CRISP has near-zero supply-chain control: patient's own HSPCs → apheresis/cell collection at an authorized treatment center → shipped to Vertex-coordinated manufacturing (third-party CDMOs incl. Lonza and RoslinCT, named in the parallel ToolGen litigation) → Cas9 RNP edit at the BCL11A erythroid enhancer → edited cells returned → myeloablative busulfan conditioning → infusion. The chokepoint is the first step: specialists at four sickle centers told STAT (Feb 2026) the binding constraint is that they cannot collect enough cells to manufacture a dose — the apheresis/mobilization yield, not demand, is gating the ramp. This is the single most important fact about the near-term Casgevy cash story, and CRISP cannot fix it — Vertex and the ATCs own that node.

Owned in-vivo pipeline (CTX310/340/321/460) — CRISP controls more: proprietary LNP delivery platform (validated lipid-nanoparticle, IV-infused, liver-tropic) + CRISPR/Cas9 or SyNTase editors → no apheresis, no ex-vivo manufacturing, no conditioning → an off-the-shelf vial. This is the structural reason the in-vivo franchise is the better long-term business: it dissolves the very bottleneck strangling Casgevy. zugo-cel (CAR-T) is made at CRISP's own Framingham GMP facility (leased through 2036).

Single-source / chokepoint flags: (1) Casgevy apheresis yield; (2) busulfan conditioning toxicity gates the eligible-patient funnel; (3) LNP raw materials / ionizable lipids are a quiet industry-wide dependency; (4) the Charpentier-licensed IP is itself a "supply" of freedom-to-operate now under ToolGen attack (see Lens 10).

Lens 3 · Competitive Advantages (moats)

Real moats:

• First-mover + only-commercial. CRISP is the only CRISPR-focused biotech with an approved, marketed product. Intellia, Beam, Editas are all still pre-approval. That's a genuine 2–3 year lead in regulatory, manufacturing and payer learning — even if Vertex captured most of the value.
• Platform breadth. Four modalities (ex vivo, in vivo CRISPR, in vivo SyNTase, CAR-T) off one editing core, plus a proprietary next-gen correction platform (SyNTase — compact Cas9 + engineered polymerases, AI-optimized) that leapfrogs prime editing on the company's telling.
• Balance-sheet moat. ~$2.44B cash vs Intellia ~$0.4B, Editas ~$0.12B. In a sector where the bear case is always "runs out of money before the data," CRISP can fund itself through multiple readout cycles and a recession — a durable edge over thinner-capitalized peers.
• Charpentier IP estate — foundational Cas9 patents, exclusively licensed. A moat and a liability (Lens 10).

Bargaining power — weak where it counts. On Casgevy, Vertex holds the whip: it controls development, manufacturing, commercialization and pricing; CRISP is a 40% passive economic participant that "cannot control the extent or effectiveness of commercialization efforts" and warns its "revenues from CASGEVY may fall below expectations". On the owned in-vivo programs CRISP has full control — which is precisely why the equity story must migrate there.

Verdict: the moat is platform + cash + first-mover, not pricing power. The crown jewel (Casgevy) is mortgaged to Vertex; the unencumbered assets are still pre-proof.

Lens 4 · Segments

CRISP operates as one reportable segment and recognizes essentially no product/segment revenue, so a classic product-by-geography revenue bridge does not exist. The honest "segment" view is where the money goes, not where it comes from.

Reported revenue (de minimis) — FY2025 vs FY2024:

The $35.0M collaboration-revenue collapse is not deterioration — it's the absence of a one-time 2024 Vertex milestone. Total revenue is meaningless for this name; the P&L is an expense map.

Operating expense "segments" — FY2025:

The decisive move: collaboration expense nearly doubled to $213.5M because the $110.3M annual cost-deferral cap on the Casgevy program ended in 2025 — CRISP now absorbs its full 40% of Vertex's rising commercial/manufacturing spend with no deferral relief. So as Casgevy commercializes, CRISP's reported losses widen before they narrow. The one encouraging data point: in Q1 2026 collaboration expense fell to $45.9M (from $57.5M YoY) "primarily attributable to an increase in our share of CASGEVY revenue" — the first quarter where the Casgevy ramp visibly improved CRISP's net economics.

Geography of cash: of $2,441.8M at Q1 2026, ~$305.2M is held outside the US.

---

Phase B — Measure performance (operating + clinical overlay)

Lens 5 · Earnings Result + Pipeline-by-Phase

Latest print — Q1 2026 (reported May 4, 2026):

• Total revenue $1.5M (collaboration $1.0M + grant $0.5M) — irrelevant by design.
• R&D $68.6M; G&A $17.2M; collaboration expense, net $45.9M → total opex $131.7M.
• Loss from operations $(130.2)M; net loss $(122.9)M; EPS $(1.28) vs $(1.58) PY — loss narrowed YoY.
• Cash/marketable securities $2,441.8M; accumulated deficit $2,070.5M; ~96.4M shares out.
• vs consensus: this is a pre-revenue developer — "beat/miss" runs on cash burn + pipeline, not EPS. Burn improved (collaboration expense −20% YoY on better Casgevy economics; net loss −$13.1M YoY). n/a — no EPS consensus is meaningful for a name with no product revenue on its books.

Balance-sheet flags: clean. $2.44B liquid, total liabilities only $343M (pre-note), no going-concern doubt; auditor-attested ICFR effective. The one structural flag is the near-doubling of share count over 24 months (85.7M → 96.4M) via serial ATM sales and a Feb-2024 $280M registered direct — chronic dilution is the cost of being pre-revenue (see Lens 10).

Pipeline by phase (the asset table is the company):

PoS (illustrative, by stage convention): Casgevy ~100% (approved); CTX310 Phase 1b cardio ~20–30%; zugo-cel autoimmune ~15–25%; early in-vivo ~10–15%.

Lens 6 · Earnings Calls (sentiment trend)

No transcripts on disk (transcripts/ empty). From the public update cadence:

• Tone arc: "Casgevy launch story" (2024) → "catalyst-rich pipeline year" (2025) → "2026 is a data year" (2026). Management has deliberately shifted the narrative center of gravity off Casgevy and onto the owned in-vivo + CAR-T readouts — a tacit acknowledgment that the Casgevy ramp is slower and less CRISP-controlled than hoped.
• Recurring phrases: "first and only approved CRISPR therapy," "transformative/functional cure," "broadest pipeline in gene editing," "disciplined capital allocation."
• What they stopped emphasizing: specific Casgevy patient-count targets and revenue trajectory — consistent with the cell-collection bottleneck STAT surfaced. The emphasis moved to ATC activation (an input they can show progress on: 75 ATCs hit) rather than infusions (the output that's lagging).

Lens 7 · Comps + Mechanism Comparables

Pure-play CRISPR/gene-editing peer set. All are loss-making and pre-meaningful-revenue, so P/E, EV/EBIT, dividend yield and 5-yr ROE are n/a across the board — the relevant axes are market cap, cash, runway, and lead-asset stage.

Reads: (1) CRSP is the category heavyweight — biggest cap and biggest cash, and the only approved product. (2) Verve's acquisition by Eli Lilly (Jul 2025) is a hard validation marker for in-vivo cardiovascular editing — exactly CTX310/CTX340's lane — and arguably puts a strategic-takeout floor under CRISP's in-vivo franchise. (3) Mechanism comps: CTX310 competes vs Verve/Lilly (in-vivo ANGPTL3/PCSK9) and the entrenched injectable RNAi/antibody cardio drugs; zugo-cel competes in the crowded allogeneic CAR-T-for-autoimmune race (vs Cabaletta, Kyverna, and big-pharma allo programs). Casgevy's only direct cell-therapy comp is lovo-cel (bluebird) — but the real competition is the bottleneck, not a rival.

Provenance-critical: no forward EV/Sales or P/E multiple is sourced or computable for these pre-revenue names — n/a, not fabricated.

Lens 8 · Stock-Price Catalysts (what moves CRSP >5%)

Five-year pattern:

• +18.2% (Jul 16, 2025) — a $51.49M insider purchase by director George Simeon; +11.9% (Jul 2, 2025). The tape reacts violently to insider buying — a tell that the float is sentiment-driven and starved for conviction signals.
• Casgevy approvals (Dec 2023 SCD / Jan 2024 TDT) — the foundational re-rating events.
• CTX310 positive Phase 1 (AHA late-breaker + NEJM publication, 2025) — in-vivo proof-of-concept; the clearest evidence the market will pay up for the owned pipeline, not just Casgevy.
• Casgevy commercial-pace disappointments (the STAT cell-collection story, Feb 2026) — the downside driver: when the bottleneck narrative surfaces, the stock fades.
• 1-yr total shareholder return ~+35% into mid-2026.

What the market actually reacts to: (1) owned-pipeline clinical data (CTX310, zugo-cel) — up; (2) insider buying — up, hard; (3) Casgevy ramp/uptake friction — down. It does not trade on reported revenue or EPS (there effectively is none). This makes the H2 2026 data cluster the single most important price event of the year.

---

Phase C — Judge people & books (+ science & exclusivity overlay)

Lens 9 · Management

CEO & Chairman: Dr. Samarth ("Sam") Kulkarni — CEO since 2017, Chairman since 2023; ex-McKinsey partner (pharma/medical-products). As President/CBO he architected the franchise-defining Vertex and Bayer partnerships.

• Track record: delivered the world's first approved CRISPR medicine — a genuine, category-defining accomplishment. Counter: the deal structure he authored (Vertex 60/40, full operational control to the partner) is also why shareholders capture so little of Casgevy's value. He's a brilliant dealmaker whose signature deal underwhelms for this equity.
• Skin in the game — a mild flag. Direct ownership only ~219,823 shares (~0.24%), and he sold 90,000 shares (~$5M) in Jan 2026. FY comp $33.18M, ~97.8% equity/bonus — heavy pay, light retained ownership, regular selling. Not disqualifying for a hired-gun-CEO archetype, but it's not founder-style alignment.
• Capital allocation: disciplined defensively (built a $2.4B war chest, cut R&D headcount/SBC in 2025) and opportunistic offensively (the $96.3M Sirius IPR&D bet on FXI siRNA; the March-2026 $600M convert that diversified financing away from pure dilution). No buybacks (correct — burns cash); no value-destructive M&A. ROE/ROIC are structurally negative (pre-revenue) so not a useful scorecard yet.
• Archetype: professional manager / strategist-CEO, not a bench scientist-founder. For a platform that now needs commercial and clinical execution over discovery theater, that's arguably the right archetype — provided the owned pipeline delivers.

Lens 10 · Forensic Red Flags + Regulatory + Science/Exclusivity

Accounting risk — low, with two real watch-items:

• ASC 808 collaboration accounting is the whole ballgame. Casgevy economics run through one net line ("Collaboration expense, net," $213.5M FY2025), not gross revenue/COGS. This is GAAP-correct but opaque — investors cannot see Casgevy gross sales, CRISP's gross share, or unit economics from CRISP's statements; you must triangulate via Vertex's disclosures (Vertex reported ~$43M Casgevy product revenue in Q1 2025 ). Low fraud risk, high interpretability risk.
• Acquired IPR&D ($96.3M, Sirius, 2025) expensed immediately — clean treatment, but it means a chunk of "R&D" is deal premium, not bench spend; normalize for it when trending opex.
• SBC is large but declining ($34.4M R&D SBC FY2025 vs $47.9M FY2024) — going the right way; not flattering a non-GAAP figure because the company doesn't lean on adjusted EPS.
• Dilution is the genuine shareholder cost: APIC $3.29B→$3.86B and shares 85.7M→96.4M in 24 months. The March-2026 $600M 1.125% convert (conv. price ~$76.56, due 2031, ~11.4M max shares) is a better instrument — cheap coupon, out-of-the-money strike, first real debt — and signals management is finally protecting the equity from grind-down dilution.
• No related-party red flags; no receivables/inventory games (there's no product revenue to manipulate). Cash-vs-earnings divergence is the normal pre-revenue burn (operating cash −$345M FY2025).

Regulatory findings. Per regulatory/regulatory-findings.md (SEC EDGAR EFTS, LR + AAER, 2021-06-18→2026-06-18): zero SEC Litigation Releases, zero AAERs naming the company. Non-SEC web sweep (FTC/DOJ/FDA/CFPB + settlement/penalty terms): no enforcement actions found. 10-K Item 3 (Legal Proceedings) discloses ordinary-course IP litigation and, materially, that in Q4 2025 ToolGen, Inc. sued CRISP (and others) alleging Casgevy infringes a ToolGen CRISPR/Cas9 patent.

The IP overhang — the most underrated risk:

• ToolGen has escalated a global campaign over its RNP-delivery patents (the method of delivering Cas9 as a preassembled protein-RNA complex — core to how Casgevy is made): UK High Court (Apr 2025), Netherlands/Hague vs Lonza (Sept 2025), US (Nov 2025, US Patent 12,473,559), plus EP 4 357 457 in Europe. Vertex — as the JDCA controller and manufacturer — is leading the defense and pre-emptively filed a nullity suit in the Netherlands (Feb 2025). ToolGen says it seeks licensing/compensation, not an injunction — i.e. a royalty-stacking threat on an already-thin 40% economic share.
• Broad vs CVC (UC Berkeley/Charpentier): the foundational Cas9 priority interference was revived by the Federal Circuit. CRISP licenses the CVC/Charpentier side — an adverse outcome could cloud freedom-to-operate or force payments to the Broad. A multi-year structural overhang inherent to the whole CRISPR field.

Net: books are clean; the red flags are dilution (improving) and IP/freedom-to-operate (worsening) — not accounting.

Science & exclusivity. Mechanism validation is strong: Casgevy is approved (regulators accepted the BCL11A approach); CTX310 produced NEJM-published, durable in-vivo lipid lowering — de-risking the LNP+Cas9 liver platform; zugo-cel's drug-free SLE remissions validate allo-CAR-T-for-autoimmune. Exclusivity: orphan/RMAT/CNPV designations (Casgevy-SCD won a Commissioner's National Priority Voucher Nov 6, 2025, a potential review accelerator for the peds sBLA). The exclusivity risk is not patent-cliff (assets are early) — it's the ToolGen/Broad freedom-to-operate question above.

---

Phase D — Project & stress-test (rNPV + runway-to-catalyst overlay)

Lens 11 · Forward Projection — rNPV + Runway-to-Catalyst

For a development-stage name, EPS is the wrong unit (CRISP will post net losses for years). The right questions: (a) does cash reach the value-inflection catalysts, and (b) what is the lead-asset rNPV?

Runway (the answer that matters): ~$2,441.8M cash (Q1 2026) + management's own "≥24 months" guidance, before the $600M convert proceeds and any Vertex milestones. At ~$110M/qtr operating burn (Q1 2026 operating cash −$108.9M), straight-line runway is ~5+ years — comfortably past the entire H2 2026 catalyst cluster (CTX310, zugo-cel, CTX611) and the 2027 in-vivo readouts. Runway is a non-issue — the rarest thing to be able to say in gene-editing. This is CRISP's defining defensive advantage.

Illustrative EPS path (losses; bottom-up from Q1 2026 run-rate, all ``):

• Opex base: ~$520–560M/yr (FY2025 $668M less the one-off $96.3M Sirius IPR&D ≈ $572M; trending flat-to-down on R&D discipline).
• Revenue: effectively $0 reported; Casgevy upside arrives as a shrinking collaboration-expense line, not revenue.
• FY2026E net loss ~$(480)–(520)M → EPS ~$(4.90)–(5.30); FY2027E ~$(4.50)–(5.00); FY2028E ~$(4.00)–(4.80), narrowing only as Casgevy economics turn CRISP's 40% share net-positive. These are loss estimates; the equity is valued on rNPV/catalysts, not earnings.

Lead-asset rNPV (rough, every input labeled ``):

• Casgevy (CRISP 40% share): eligible severe-SCD+TDT addressable ~?; assume a steady-state where Casgevy reaches ~$1.0–1.5B annual net product profit pool at maturity → CRISP 40% ≈ $400–600M/yr; at ~3–4× a de-risked specialty cash stream, CRISP's Casgevy stub ≈ $1.5–2.5B.
• CTX310 (in-vivo cardio): peak-sales TAM large (ANGPTL3/lipid); PoS ~25%; the Verve/Lilly takeout frames optionality at $1–3B risk-adjusted if Phase 2 confirms.
• zugo-cel autoimmune + remaining pipeline + SyNTase platform: call it $1–2B blended optionality.
• Plus ~$2.44B net cash. Sum-of-parts lands broadly around-to-above the ~$5.1B market cap — i.e. the market is paying roughly cash + Casgevy stub and ascribing modest value to the owned pipeline. The asymmetry is in the H2 2026 data.

Brier forecast (logged separately, not run here per --watchlist rules): the scoreable binary would be "CTX310 advances to/initiates Phase 2 (or a regist(-enabling) study) by YE2027," not an EPS line.

Lens 12 · Bull vs Bear

Bull case. The only company to have shipped CRISPR owns a $2.4B war chest, a fortress runway, and a wholly-controlled in-vivo + CAR-T pipeline entering a dense H2 2026 data catalysts window — with CTX310 already NEJM-validated and zugo-cel printing drug-free SLE remissions. Casgevy's 40% stub, today a widening-expense drag, inflects to a net contributor as the ramp matures (already visible in Q1 2026's −20% YoY collaboration expense). The Lilly–Verve deal proves strategics will pay up for in-vivo cardio editing — a takeout/partnership floor under CTX310/340. SyNTase is a credible next-gen correction platform. If even one owned in-vivo asset reaches Phase 2 with clean data, the market re-rates the pipeline it's currently getting close to free.

Bear case (permanent-impairment risks).

1. The Casgevy bottleneck is structural, not transient. If apheresis cell-collection yields stay the binding constraint, the "nearly triple in 2026" guidance slips for years and the 40% stub never becomes the cash engine bulls model.
2. CRISP doesn't control its own crown jewel. Vertex runs everything; CRISP is a price-taker on its biggest asset and explicitly warns revenue may disappoint.
3. IP/freedom-to-operate. ToolGen's multi-front RNP litigation + the revived Broad–CVC interference could stack royalties on a thin share or cloud the platform.
4. Chronic dilution — 12%+ share growth in 24 months; pre-revenue names raise on weakness.

Pre-mortem (18 months out, thesis broke): H2 2026 CTX310 update disappoints (efficacy fades or a safety signal in a systemic in-vivo edit), zugo-cel autoimmune doesn't separate from a crowded allo-CAR-T field, Casgevy infusions stay supply-gated, and ToolGen wins a US ruling — the stock loses its pipeline premium and trades toward cash (~$25/sh).

Are multiples too high? Inapplicable (no earnings). On sum-of-parts, the market is paying ~cash + a modest Casgevy/pipeline premium — not demanding — which is why the risk/reward is data-dependent rather than valuation-stretched.

Contrarian view (what the market refuses to see): the consensus still frames CRSP as "the Casgevy company." The real call is that Casgevy is a capped, Vertex-controlled annuity and the equity is actually an in-vivo LNP-editing option — the market is mispricing CRSP by anchoring on the asset that matters least to incremental value.

Lens 13 · Devil's Advocate (short-seller)

Dismantling the bull case:

• "First and only approved" is a vanity moat. CRISP captures 40% of a drug it doesn't run, recognized as a cost. The approval enriched Vertex; CRISP shareholders got a widening loss and serial ATM raises. Being "first" to a partner-controlled product is not durable economics.
• Revenue concentration is total and externally controlled. ~100% of commercial exposure is one program, one partner, one bottlenecked supply chain. If Vertex deprioritizes Casgevy or the apheresis problem persists, there's no offset — the owned pipeline is years from revenue.
• The moat bulls cite is mostly cash. $2.4B funds attempts, not a guaranteed outcome; Beam ($1.2B, into mid-2029) and Intellia (into 2028) are also funded through their catalysts. Cash buys time, not data.
• Most dangerous competitor bulls underrate: Eli Lilly (via Verve) in in-vivo cardiovascular editing — deeper pockets, full control, same ANGPTL3/PCSK9 lane as CTX310. CRISP could be out-resourced in exactly the franchise that's supposed to be its future.
• Worst capital-allocation marks: authoring a 60/40 partner-controlled deal on the flagship; $96.3M expensed into a Phase-2 siRNA asset (Sirius) of unproven strategic fit; 12% dilution in 24 months.
• Assumptions that must hold for ~$53: Casgevy inflects to net-positive and at least one owned in-vivo asset delivers clean H2-2026 data and ToolGen/Broad don't impair freedom-to-operate. If owned-pipeline growth disappoints 20–30%, the pipeline premium evaporates and the stock trades toward net cash (~$25/sh) — a ~50% drawdown.
• Single permanent-impairment scenario: a systemic in-vivo CRISPR safety event (off-target/immunogenicity in CTX310 or a peer's liver program) that re-rates the entire in-vivo modality — plausibility low-but-non-trivial, and it would hit the exact franchise the bull thesis depends on.

Lens 14 · Management Questions (ordered by information value)

1. What is the actual gating constraint on Casgevy infusions — apheresis cell-collection yield, conditioning eligibility, or payer authorization — and what concretely changes it in 2026 vs 2027?
2. At what Casgevy net-revenue level does your 40% share turn net-positive to the P&L (collaboration expense → contribution), and what's the timeline?
3. On CTX310, what efficacy/durability/safety bar in the H2-2026 update would you consider Phase-2/registration-enabling, and what would make you stop?
4. How do you assess ToolGen's RNP-delivery patents' validity and your indemnification/cost-sharing with Vertex if they prevail in any jurisdiction? Quantify the royalty-stacking exposure on Casgevy.
5. Given Lilly's acquisition of Verve, how do you compete on resources in in-vivo cardiovascular editing — partner CTX310/340, or go it alone?
6. With ~$2.4B cash + the $600M convert, what is the capital-allocation priority stack — and under what conditions do you in-license/acquire vs return capital?
7. What is the strategic rationale and success metric for the $96.3M Sirius/CTX611 FXI bet, and how does siRNA fit a gene-editing platform thesis?
8. What is SyNTase's differentiated, independently-validated advantage over base/prime editing, and when does CTX460 give the first clinical proof?
9. How should investors value CRISP independent of Vertex — what do you want the owned-pipeline SOTP to be worth in 3 years?
10. Where could the revived Broad–CVC interference leave your Charpentier-licensed freedom-to-operate, and what's the contingency?
11. zugo-cel autoimmune is entering a crowded allo-CAR-T field — what's the durability/safety edge over Cabaletta, Kyverna and big-pharma allo programs?
12. What gives you confidence apheresis/manufacturing scales for a broad SCD population, not just the early-adopter cohort?
13. Insider ownership is ~0.24% and there's recent selling — how should shareholders read management's personal conviction?
14. What is the realistic peds-5–11 Casgevy timeline given the CNPV, and how much does it expand the funnel?
15. Name the one program whose failure would most damage the equity story — and your honest probability it succeeds.

---